A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- Registration Number
- NCT00002364
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
To obtain preliminary evidence of antiretroviral activity of 1592U89 when administered in combination with other specific NRTI agents in NRTI experienced patients and to assess the safety and tolerance of multiple oral doses of 1592U89 when administered in combination with specific marketed NRTIs.
- Detailed Description
Patients will all receive oral doses of 1592U89 in combination with protocol specific current antiretroviral therapy. The treatment groups will be assigned based on each subject's previous NRTI experience.
The study medication is self administered and all evaluations will be performed on an outpatient basis. Patients will be seen at day 0 and weeks 2, 4, 12, 16, 20 and 24.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (8)
Marin County Specialty Clinic
🇺🇸Greenbrae, California, United States
Kraus Med Partners
🇺🇸Los Angeles, California, United States
ViRx Inc
🇺🇸San Francisco, California, United States
IDC Research Initiative
🇺🇸Altamonte Springs, Florida, United States
North Broward Hosp District
🇺🇸Fort Lauderdale, Florida, United States
AIDS Research Consortium of Atlanta
🇺🇸Atlanta, Georgia, United States
Univ of Kentucky Med Ctr
🇺🇸Lexington, Kentucky, United States
Beth Israel Med Ctr
🇺🇸New York, New York, United States
Marin County Specialty Clinic🇺🇸Greenbrae, California, United States